Elizabeth E. Reed, Chief Legal Officer and General Counsel at Travere Therapeutics ($TVTX), sold shares on the open market eight times over the past year, totaling $1.23 million. Her most recent sale occurred on February 17, 2026. These sales rank her 4,455th among 11,678 insiders by value sold, below the average of $8.59 million across 6.4 transactions per insider. She made no open market purchases in this period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| April 1, 2026 | Travere Therapeutics, Inc. | $TVTX | REED ELIZABETH E | Chief Legal Officer and GC | M | Common Stock | 10000 | $15.46 | 115,211.0000 | 89,211,813 | 9.50% | 0.01% |
| April 1, 2026 | Travere Therapeutics, Inc. | $TVTX | REED ELIZABETH E | Chief Legal Officer and GC | M | Employee stock option (right to buy) | 10000 | $0.00 | 45,000.0000 | 89,211,813 | 18.18% | 0.01% |
| April 1, 2026 | Travere Therapeutics, Inc. | $TVTX | REED ELIZABETH E | Chief Legal Officer and GC | S | Common Stock | 10000 | $30.00 | 105,211.0000 | 89,211,813 | 8.68% | 0.01% |
| March 16, 2026 | Travere Therapeutics, Inc. | $TVTX | REED ELIZABETH E | Chief Legal Officer and GC | M | Employee stock option (right to buy) | 10000 | $0.00 | 10,000.0000 | 89,211,813 | 50.00% | 0.01% |
| March 16, 2026 | Travere Therapeutics, Inc. | $TVTX | REED ELIZABETH E | Chief Legal Officer and GC | M | Common Stock | 10000 | $19.08 | 115,211.0000 | 89,211,813 | 9.50% | 0.01% |
| March 16, 2026 | Travere Therapeutics, Inc. | $TVTX | REED ELIZABETH E | Chief Legal Officer and GC | S | Common Stock | 10000 | $28.09 | 105,211.0000 | 89,211,813 | 8.68% | 0.01% |
| Feb. 17, 2026 | Travere Therapeutics, Inc. | $TVTX | REED ELIZABETH E | Chief Legal Officer and GC | M | Employee stock option (right to buy) | 10000 | $0.00 | 20,000.0000 | 89,211,813 | 33.33% | 0.01% |
| Feb. 17, 2026 | Travere Therapeutics, Inc. | $TVTX | REED ELIZABETH E | Chief Legal Officer and GC | S | Common Stock | 4321 | $28.26 | 105,211.0000 | 89,211,813 | 3.94% | 0.00% |
| Feb. 17, 2026 | Travere Therapeutics, Inc. | $TVTX | REED ELIZABETH E | Chief Legal Officer and GC | S | Common Stock | 5679 | $27.50 | 109,532.0000 | 89,211,813 | 4.93% | 0.01% |
| Feb. 17, 2026 | Travere Therapeutics, Inc. | $TVTX | REED ELIZABETH E | Chief Legal Officer and GC | M | Common Stock | 10000 | $19.08 | 115,211.0000 | 89,211,813 | 9.50% | 0.01% |
| Feb. 4, 2026 | Travere Therapeutics, Inc. | $TVTX | REED ELIZABETH E | Chief Legal Officer and GC | S | Common Stock | 2485 | $32.07 | 105,720.0000 | 89,211,813 | 2.30% | 0.00% |
| Feb. 4, 2026 | Travere Therapeutics, Inc. | $TVTX | REED ELIZABETH E | Chief Legal Officer and GC | S | Common Stock | 509 | $32.74 | 105,211.0000 | 89,211,813 | 0.48% | 0.00% |
| Feb. 3, 2026 | Travere Therapeutics, Inc. | $TVTX | REED ELIZABETH E | Chief Legal Officer and GC | S | Common Stock | 7175 | $32.12 | 108,205.0000 | 89,211,813 | 6.22% | 0.01% |
| Jan. 31, 2026 | Travere Therapeutics, Inc. | $TVTX | REED ELIZABETH E | Chief Legal Officer and GC | A | Employee stock option (right to buy) | 66960 | $0.00 | 66,960.0000 | 89,211,813 | 9999.99% | 0.08% |
| Jan. 31, 2026 | Travere Therapeutics, Inc. | $TVTX | REED ELIZABETH E | Chief Legal Officer and GC | A | Common Stock | 25110 | $0.00 | 115,380.0000 | 89,211,813 | 27.82% | 0.03% |
| Jan. 20, 2026 | Travere Therapeutics, Inc. | $TVTX | REED ELIZABETH E | Chief Legal Officer and GC | M | Common Stock | 10000 | $19.08 | 100,270.0000 | 89,211,813 | 11.08% | 0.01% |
| Jan. 20, 2026 | Travere Therapeutics, Inc. | $TVTX | REED ELIZABETH E | Chief Legal Officer and GC | M | Employee stock option (right to buy) | 10000 | $0.00 | 30,000.0000 | 89,211,813 | 25.00% | 0.01% |
| Jan. 20, 2026 | Travere Therapeutics, Inc. | $TVTX | REED ELIZABETH E | Chief Legal Officer and GC | S | Common Stock | 10000 | $27.34 | 90,270.0000 | 89,211,813 | 9.97% | 0.01% |
| Sept. 22, 2025 | Travere Therapeutics, Inc. | $TVTX | REED ELIZABETH E | Chief Legal Officer and GC | M | Common Stock | 10000 | $19.08 | 99,878.0000 | 78,888,861 | 11.13% | 0.01% |
| Sept. 22, 2025 | Travere Therapeutics, Inc. | $TVTX | REED ELIZABETH E | Chief Legal Officer and GC | S | Common Stock | 10000 | $25.00 | 89,878.0000 | 78,888,861 | 10.01% | 0.01% |
| Sept. 22, 2025 | Travere Therapeutics, Inc. | $TVTX | REED ELIZABETH E | Chief Legal Officer and GC | M | Employee stock option (right to buy) | 10000 | $0.00 | 40,000.0000 | 78,888,861 | 20.00% | 0.01% |
| May 5, 2025 | Travere Therapeutics, Inc. | $TVTX | REED ELIZABETH E | Chief Legal Officer and GC | S | Common Stock | 4920 | $21.05 | 89,482.0000 | 78,888,861 | 5.21% | 0.01% |
| May 2, 2025 | Travere Therapeutics, Inc. | $TVTX | REED ELIZABETH E | Chief Legal Officer and GC | M | Common Stock | 4920 | $0.00 | 94,402.0000 | 78,888,861 | 5.50% | 0.01% |
| May 2, 2025 | Travere Therapeutics, Inc. | $TVTX | REED ELIZABETH E | Chief Legal Officer and GC | M | Performance-based restricted stock units | 4920 | $0.00 | 4,920.0000 | 78,888,861 | 50.00% | 0.01% |
| Feb. 10, 2025 | Travere Therapeutics, Inc. | $TVTX | REED ELIZABETH E | SVP, GC & CORPORATE SECRETARY | M | Performance-based restricted stock units | 8000 | $0.00 | 0.0000 | 78,888,861 | 100.00% | 0.01% |
| Feb. 10, 2025 | Travere Therapeutics, Inc. | $TVTX | REED ELIZABETH E | SVP, GC & CORPORATE SECRETARY | M | Common Stock | 8000 | $0.00 | 97,482.0000 | 78,888,861 | 8.94% | 0.01% |
| Feb. 12, 2025 | Travere Therapeutics, Inc. | $TVTX | REED ELIZABETH E | SVP, GC & CORPORATE SECRETARY | S | Common Stock | 8000 | $23.53 | 89,482.0000 | 78,888,861 | 8.21% | 0.01% |
| Jan. 31, 2025 | Travere Therapeutics, Inc. | $TVTX | REED ELIZABETH E | SVP, GC & CORPORATE SECRETARY | A | Employee stock option (right to buy) | 58000 | $0.00 | 58,000.0000 | 78,888,861 | 9999.99% | 0.07% |
| Feb. 3, 2025 | Travere Therapeutics, Inc. | $TVTX | REED ELIZABETH E | SVP, GC & CORPORATE SECRETARY | S | Common Stock | 8951 | $19.78 | 89,482.0000 | 78,888,861 | 9.09% | 0.01% |
| Jan. 31, 2025 | Travere Therapeutics, Inc. | $TVTX | REED ELIZABETH E | SVP, GC & CORPORATE SECRETARY | A | Common Stock | 21500 | $0.00 | 98,433.0000 | 78,888,861 | 27.95% | 0.03% |
| Jan. 22, 2025 | Travere Therapeutics, Inc. | $TVTX | REED ELIZABETH E | SVP, GC & CORPORATE SECRETARY | S | Common Stock | 2437 | $19.46 | 76,933.0000 | 78,888,861 | 3.07% | 0.00% |
| Sept. 9, 2024 | Travere Therapeutics, Inc. | $TVTX | REED ELIZABETH E | SVP, GC & CORPORATE SECRETARY | S | Common Stock | 4387 | $11.52 | 78,633.0000 | 74,267,418 | 5.28% | 0.01% |
| Sept. 5, 2024 | Travere Therapeutics, Inc. | $TVTX | REED ELIZABETH E | SVP, GC & CORPORATE SECRETARY | A | Common Stock | 6750 | $0.00 | 83,020.0000 | 74,267,418 | 8.85% | 0.01% |
| Jan. 31, 2024 | Travere Therapeutics, Inc. | $TVTX | REED ELIZABETH E | SVP, GC & CORPORATE SECRETARY | A | Employee stock option (right to buy) | 65000 | $0.00 | 65,000.0000 | 74,267,418 | 9999.99% | 0.09% |
| Feb. 1, 2024 | Travere Therapeutics, Inc. | $TVTX | REED ELIZABETH E | SVP, GC & CORPORATE SECRETARY | S | Common Stock | 2174 | $8.53 | 78,860.0000 | 74,267,418 | 2.68% | 0.00% |
| Jan. 31, 2024 | Travere Therapeutics, Inc. | $TVTX | REED ELIZABETH E | SVP, GC & CORPORATE SECRETARY | A | Common Stock | 25000 | $0.00 | 81,034.0000 | 74,267,418 | 44.62% | 0.03% |
| Feb. 1, 2024 | Travere Therapeutics, Inc. | $TVTX | REED ELIZABETH E | SVP, GC & CORPORATE SECRETARY | S | Common Stock | 2590 | $8.86 | 76,270.0000 | 74,267,418 | 3.28% | 0.00% |
| Jan. 23, 2024 | Travere Therapeutics, Inc. | $TVTX | REED ELIZABETH E | SVP, GC & CORPORATE SECRETARY | S | Common Stock | 2062 | $8.96 | 56,034.0000 | 74,267,418 | 3.55% | 0.00% |